Kyverna Therapeutics, Inc. (KYTX)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Kyverna Therapeutics, Inc.(KYTX) Shareholders
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Kyverna Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Reach Out To The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / December 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering ("IPO") conducted on February 8, 2024, are encouraged to contact the firm before February 7, 2025.
Investors in Kyverna Therapeutics, Inc. Should Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
February 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against KYTX
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / If you suffered a loss on your Kyverna Therapeutics, Inc. (NASDAQ:KYTX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Kyverna Therapeutics, Inc. - KYTX
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ:KYTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Kyverna Therapeutics, Inc. - KYTX
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna" or the "Company") (NASDAQ:KYTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / December 11, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Kyverna securities pursuant to the registration statement and prospectus issued in connection with the Company's February 8, 2024 initial public offering ("IPO").
The Schall Law Firm Urges Shareholder Participation In A Securities Fraud Case Against Kyverna Therapeutics Inc
LOS ANGELES, CA / ACCESSWIRE / December 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces the firm has filed a class action lawsuit against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the federal securities laws. Investors who purchased the Company's securities pursuant and/or traceable to the Company's offering documents issued in connection with its initial public offering ("IPO") conducted on February 8, 2024, are encouraged to contact the firm before February 7, 2025.
KYTX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Kyverna securities pursuant to the registration statement and prospectus issued in connection with the Company's February 8, 2024 initial public offering ("IPO").
Kyverna Therapeutics Sued for Securities Fraud; Investors Should Contact Block & Leviton to Learn How They Might Recover Losses
BOSTON, MA / ACCESSWIRE / December 10, 2024 / Block & Leviton announces that a securities fraud lawsuit has been filed against Kyverna Therapeutics, Inc. (Nasdaq:KYTX) and certain of its executives. Investors who have lost money in their Kyverna Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses.
Kyverna Therapeutics, Inc. May Have Committed Securities Fraud And The Schall Law Firm Encourages Shareholders To Join An Inquiry
LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Is Looking Into Whether Kyverna Therapeutics Inc Violated Securities Laws And Investors Are Invited To Participate
LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Kyverna Therapeutics, Inc. ("Kyverna" or "the Company") (NASDAQ:KYTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
